

1           **Selectivity among anti- $\sigma$  factors by *Mycobacterium tuberculosis* ClpX influences**  
2                           **intracellular levels of Extracytoplasmic Function  $\sigma$  factors**

3           Running Title: Substrate specificity of ClpX governs  $\sigma$  factor regulation

4           **Anuja C Joshi<sup>a</sup>, Prabhjot Kaur<sup>b</sup>, Radhika K Nair<sup>a</sup>, Deepti S Lele<sup>a</sup>, Vinay Kumar**  
5                           **Nandicoori<sup>b</sup> and Balasubramanian Gopal<sup>a,#</sup>**

6           <sup>a</sup>Molecular Biophysics Unit, Indian Institute of Science, Bangalore-560012, India

7           <sup>b</sup>National Institute of Immunology, New Delhi-11001, India

8           # To whom correspondence should be addressed. Tel: 91 (080) 2293 3219; Email:

9   bgopal@iisc.ac.in

10   **Abstract:** Extracytoplasmic Function  $\sigma$  factors that are stress inducible are often sequestered in  
11   an inactive complex with a membrane-associated anti- $\sigma$  factor. *M. tuberculosis* membrane-  
12   associated anti- $\sigma$  factors have a small stable RNA gene A-like degron for targeted proteolysis.  
13   Interaction between the unfoldase, ClpX, and the substrate with an accessible degron initiates  
14   energy-dependent proteolysis. Four anti- $\sigma$  factors with a mutation in the degron provided a set  
15   of natural substrates to evaluate the influence of the degron on degradation strength in ClpX-  
16   substrate processivity. We note that a point mutation in the degron (XXX-Ala-Ala) leads to an  
17   order of magnitude difference in the dwell time of the substrate on ClpX. Differences in  
18   ClpX/anti- $\sigma$  interactions were correlated with change in unfoldase activity. GFP chimeras or  
19   polypeptides of identical length with the anti- $\sigma$  degron also demonstrate degron-dependent  
20   variation in ClpX activity. We show that degron-dependent ClpX activity leads to differences in  
21   anti- $\sigma$  factor degradation thereby regulating the release of free  $\sigma$  from the  $\sigma$ /anti- $\sigma$  complex. *M.*

22 *tuberculosis* ClpX activity thus influences changes in gene expression by modulating the cellular  
23 abundance of ECF  $\sigma$  factors.

24 **Importance:** The ability of *Mycobacterium tuberculosis* to quickly adapt to the changing  
25 environmental stimuli occurs by maintaining protein homeostasis. Extra-cytoplasmic function  
26 (ECF)  $\sigma$  factors play a significant role in coordinating the transcription profile to changes in  
27 environmental conditions. Release of the  $\sigma$  factor from the anti- $\sigma$  is governed by the ClpXP2P1  
28 assembly. *M. tuberculosis* ECF anti- $\sigma$  factors have a ssrA-like degron for targeted degradation.  
29 A point mutation in the degron leads to differences in ClpX mediated proteolysis and affects the  
30 cellular abundance of ECF  $\sigma$ -factors. ClpX activity thus synchronizes changes in gene  
31 expression with environmental stimuli affecting *M. tuberculosis* physiology.

32 **Keywords:** gene expression regulation, sigma factors, AAA (+) Chaperone, selectivity,  
33 proteolysis

## 34 **Introduction**

35 *Mycobacterium tuberculosis* encounters diverse host microenvironments including  
36 acidification of phagosomes, nitrogen intermediates, reactive oxygen species, nutrient starvation,  
37 DNA damage, phosphate deprivation and hypoxia (1). Extracytoplasmic Function (ECF)  $\sigma$   
38 factors are non-essential and stress inducible and they contribute significantly to bacterial  
39 survival alongside one- and two-component systems (2). *M. tuberculosis* has ten ECF  $\sigma$  factors-  
40 of which four are localized in an inactive complex with membrane associated anti- $\sigma$  factors (3,  
41 4). The membrane associated anti- $\sigma$  factors (RsdA, RsmA, RskA and RslA in *M. tuberculosis*)  
42 share a common structural organization comprising of an extra-cytoplasmic domain that is a  
43 receptor for environmental stress connected to the cytoplasmic anti- $\sigma$  domain by a single trans-

44 membrane helix (Figure 1). The stress-induced release of an ECF  $\sigma$  factor from the  $\sigma$ /anti- $\sigma$   
45 factor complex governs the intra-cellular levels of these transcription initiation factors and  
46 thereby the expression of their cognate regulons. The relative cellular abundance of different  $\sigma$   
47 factors dictates the expression profile- best described by a mechanistic model referred to as the  
48 partitioning of  $\sigma$  factor space (5). Indeed, the number of different  $\sigma$  factors is correlated with the  
49 diversity of environmental conditions encountered by the bacterium (5).

50 The intracellular release of an ECF  $\sigma$  factor from the inactive membrane-associated  
51  $\sigma$ /anti- $\sigma$  complex is governed by a proteolytic cascade referred to as the Regulated Intra-  
52 membrane Proteolysis (RIP) pathway (6). This cascade is initiated by the action of a so-called  
53 site-1 protease that acts on the extracytoplasmic domain of the anti- $\sigma$  factor (6). This triggers the  
54 activity of a trans-membrane protease (site-2 protease) that dissociates the  $\sigma$ /anti- $\sigma$  complex from  
55 the membrane. The anti- $\sigma$  factor is then degraded by energy-dependent proteolytic complexes to  
56 release the bound ECF  $\sigma$  factor that can associate with the RNA polymerase and initiate  
57 transcription (Figure 1A). The intracellular proteolysis of the anti- $\sigma$  factor RseA is primarily  
58 governed by ClpXP in *Escherichia coli*, although other proteolytic assemblies also contribute to  
59 this process (7). The specific degradation of *E. coli* RseA from the  $\sigma^E$ /RseA complex is also  
60 influenced by an adaptor protein, SspB (8). *E. coli* SspB mediated interactions are crucial for  
61 effective degron recognition- while *E. coli* ClpX interacts with residues 9-11 at the C terminus of  
62 the *ssrA* degron, SspB interacts with residues 1-4 and 7 (9-11). Other *E. coli* ClpX adaptors that  
63 have been characterized are RssB and UmuD (12,13). The presence of different adaptors  
64 suggested a mechanism for the specific recruitment of diverse substrates for the ClpX unfoldase  
65 to initiate proteolysis with the serine protease ClpP in the ClpXP proteolytic complex (12).

66 ClpX comprises of a small N-terminal domain flexibly attached to the unfoldase module,  
67 the AAA+ domain (14). The AAA+ domain has multiple conserved sequence features including  
68 Walker A and Walker B motifs for ATP binding, a second region of homology (SRH) segment  
69 involved in ATP hydrolysis and sensor 2 and 3 residues that propagate conformational changes  
70 upon ATP hydrolysis to stabilize the ATP binding conformation of the unfoldase (14-18). With  
71 the two domains functioning in a concerted manner, ClpX can translocate and unfold a diverse  
72 range of substrates (19). Analysis of *E. coli* ClpX substrates suggested five distinct degra-  
73 motifs (19). Apart from adaptor proteins that enforce specificity, the N-terminal domain of *E.*  
74 *coli* ClpX is also involved in substrate recognition (15). The role of the ClpX N-terminal  
75 domain, however, differs across substrates. While the N-terminal domain substantially  
76 influences *E. coli* ClpX action on substrates like  $\lambda$ O and MuA, it is much less so for Green  
77 Fluorescent Protein (GFP) substrates with a small stable RNA gene A (*ssrA*) degra- (15).

78 The *M. tuberculosis* RIP pathway is only partially characterised. The site-1 protease that  
79 initiates the proteolytic cascade in the RIP pathway has not been identified in *M. tuberculosis*.  
80 One site-2 protease Rip1 (Rv2869c) acts on all membrane associated anti- $\sigma$  factors (RskA,  
81 RsmA, RslA and RsdA) (20,21). For comparison, in *E. coli*, the first two proteolytic steps are  
82 performed by DegS and YaeL (22,23). However, straightforward extension from the *E. coli*  
83 model for the subsequent steps is difficult as there are four membrane-associated  $\sigma$ /anti- $\sigma$   
84 complexes in *M. tuberculosis* ( $\sigma^D$ /RsdA,  $\sigma^K$ /RskA,  $\sigma^L$ /RslA and  $\sigma^M$ /RsmA) as opposed to one  
85 ( $\sigma^E$ /RseA) in *E. coli* (Figure 2A). The cytosolic step of the cascade involving intracellular  
86 proteolytic complexes is also substantially different in *M. tuberculosis* than either *E. coli* or *B.*  
87 *subtilis* (8,24). For example, *M. tuberculosis* has two ClpP protease components- ClpP1 and  
88 ClpP2 (25). Furthermore, targeted protein degradation in *E. coli* by the ClpXP complex is also

89 influenced by adaptor proteins. Unlike *E. coli*, no SspB homologue or adaptor of *M.*  
90 *tuberculosis* ClpX has been annotated or experimentally identified thus far. Nonetheless,  
91 previous studies revealed that the cytoplasmic domain of RsdA was recognised and cleaved by  
92 the *M. tuberculosis* ClpXP2P1 complex (26). The degron in *M. tuberculosis* RsdA is VAA,  
93 identical to that in *E. coli* RseA. RslA, however, was found to be resistant to ClpXP2P1  
94 degradation, despite having the *ssrA*-like degron (26). Apart from proteolytic degradation, other  
95 mechanism(s) modulate the cellular abundance of specific ECF  $\sigma$  factors by altering the rates of  
96 an ECF  $\sigma$  from an inactive  $\sigma$ /anti- $\sigma$  complex. For example, *M. tuberculosis* RslA was shown to  
97 release  $\sigma^L$  under oxidative stress conditions (27). In this case, the receptor for the redox stimulus  
98 was the Zinc binding CXXC motif in the anti- $\sigma$  factor, RslA. The release of Zinc under  
99 oxidizing conditions was seen to alter the conformation of RslA thereby releasing  $\sigma^L$ . *M.*  
100 *tuberculosis* RskA also was shown to dissociate under reducing conditions from  $\sigma^K$ , the redox  
101 sensor in this case, is the  $\sigma$  factor  $\sigma^K$  (28). All these anti- $\sigma$  factors, however, also contain an  
102 *ssrA*-like degron that is exposed upon RIP-1 (site-2 protease) activity.

103         In the regulated proteolytic cascade, the targeted proteolysis of an anti- $\sigma$  factor by the  
104 ClpXP proteolytic complex is the last step in signal transduction to effect changes in gene  
105 expression in response to environmental stress. The cytosolic domains of four *M. tuberculosis*  
106 anti- $\sigma$  factors with the *ssrA*-like degron provided a set of natural variants to understand the basis  
107 for substrate selection in *M. tuberculosis* ClpX. We note that while the N-terminal domain of  
108 ClpX is not involved in degron recognition, it influences unfoldase activity. We also describe  
109 biochemical experiments which reveal that the degron sequence governs both the substrate  
110 binding affinity as well as the kinetics of unfolding. The variation in the dwell time of the  
111 substrate on ClpX was also seen to have a direct bearing on the proteolytic degradation of the

112 anti- $\sigma$  substrates by the ClpXP2P1 complex to release free ECF  $\sigma$  factors that can initiate  
113 transcription. In effect, *M. tuberculosis* ClpX translates variation in the degron sequence into  
114 differential unfoldase activity. These degron-dependent differences in last step in the *M.*  
115 *tuberculosis* RIP cascade are thus likely to provide an additional regulatory layer for nuanced  
116 changes in the transcriptional profile in response to a stress stimulus.

## 117 **Results**

### 118 **The *ssrA*-like degron governs interactions between *M. tuberculosis* ClpX and anti- $\sigma$** 119 **substrates**

120 The binding affinity of *M. tuberculosis* ClpX with the anti- $\sigma$  substrates containing the C-terminal  
121 *ssrA*-like degron was determined by Surface Plasmon Resonance (SPR) (Figure 2B-D). As the  
122 purified anti- $\sigma$  factors are prone to aggregation, the purified substrates used in these experiments  
123 consisted of the ECF  $\sigma$  factor complexed with an anti- $\sigma$  factor containing the degron at the C-  
124 terminus. Co-expression and co-purification of the  $\sigma$ /anti- $\sigma$  factor complexes significantly  
125 improves the yield of homogenous protein samples as the  $\sigma$  or anti- $\sigma$  factors in isolation are  
126 relatively unstable (29). The last three residues (9-11) of the *ssrA* degron was shown to interact  
127 with *E. coli* ClpX (19). This feature was seen to be retained in the case of *M. tuberculosis* ClpX  
128 (26). SPR sensorgrams revealed that deletion of the terminal residues of the degron abrogated  
129 the binding of these substrate proteins to ClpX- a finding that was similar to the case where the  
130 last three residues of the degron (VAA) were replaced by a negatively charged C-terminus  
131 (VDD) (Figure 3C, Figure A1). Indeed, the finding that substrates without the degron do not  
132 bind ClpX also suggests that non-specific binding is unlikely (Figure A1). These constructs  
133 were employed as control inactive ‘degrons’ in the subsequent analysis. *M. tuberculosis* ClpX

134 bound to  $\sigma^D$ /RsdA with the highest affinity (Table 1). We note a ten-fold reduction in ClpX  
135 binding to the  $\sigma^L$ /RslA,  $\sigma^K$ /RskA and  $\sigma^M$ /RsmA complexes as compared with the the  $\sigma^D$ /RsdA  
136 substrate (Table 1). These SPR measurements were performed using freshly prepared ClpX  
137 samples. We note that ATP does not appear to be a necessary prerequisite for substrate binding.  
138 This differs from previous reports that suggested nucleotide addition as a trigger for substrate  
139 recruitment in this class of unfoldases. A related observation is that while freshly prepared ClpX  
140 samples are primarily hexameric with a small dimeric component, the hexameric species is  
141 unstable in the absence of ATP (polydispersity increases after *ca* 24 hrs). SPR sensorgrams  
142 reveal that the difference in these ClpX-  $\sigma$ /anti-  $\sigma$  interactions lies in the dissociation rate  
143 constant ( $k_d$ ) (Table 1). A comparison between the standard deviation in these measurements  
144 across different substrates is shown in Figure A2. The degrons in the four anti- $\sigma$  factors have  
145 different aliphatic residues at the ante-penultimate position (Figure 1C). A mutation in the  
146 degron of RsdA where the degron resembled that of RslA (AAA) and RsmA (GAA) shows that  
147 the binding affinity of ClpX with the  $\sigma^D$ /RsdA<sub>AAA</sub> and the  $\sigma^D$ /RsdA<sub>GAA</sub> mutant is less than wild-  
148 type  $\sigma^D$ /RsdA - comparable to ClpX interactions with the  $\sigma^L$ /RslA and the  $\sigma^M$ /RsmA complexes  
149 respectively (Figure 3A-B, Table 2). These observations suggest that although the C-terminal  
150 Alanines in the degron are involved in ClpX interactions, the ante-penultimate residue influences  
151 substrate tethering and consequently the residence time of the substrate protein on the ClpX  
152 hexamer (Table 2).

### 153 **The degron in substrates determines ClpX ATPase and unfoldase activity**

154 Processing of protein substrates by ClpX is coupled to the rate of ATP hydrolysis (30).  
155 ATPase assays revealed that differences in binding affinity of the four anti- $\sigma$  substrates to ClpX  
156 were correlated with the rate of ATP hydrolysis. That substrate binding directly influences

157 ATPase activity was evident from the observation that the ATPase activity of ClpX was highest  
158 in the presence of  $\sigma^D$ /RsdA- almost five-fold higher when compared to ClpX alone. Secondly,  
159 ClpX ATPase activity was not altered in the presence of the substrate with the inactive degron in  
160  $\sigma^D$ /RsdA (VDD). The ATPase activity of ClpX in the presence of  $\sigma^L$ /RslA was three-fold lower  
161 than that of  $\sigma^D$ /RsdA (Figure 4A, Table 3). Given that the lengths of the anti- $\sigma$  factors vary from  
162 222 to 375 residues, due to the linker between the transmembrane helix and the cytosolic anti- $\sigma$   
163 domain (Figure 1C, Table A5), the ATPase activity of ClpX was evaluated using one substrate  
164 ( $\sigma^D$ /RsdA) with varying ante-penultimate residues in the degron (Figure 4A). When the ante-  
165 penultimate residue was modified to Ala/Gly from Val in  $\sigma^D$ /RsdA, ATPase activity decreased –  
166 consistent with SPR experiments that show that ClpX binds this substrate protein with reduced  
167 affinity (Figure 4A, Table 3). In another experiment to evaluate the effect of variation of  
168 substrate size on the binding affinity or ATPase activity, ClpX ATPase activity was also  
169 evaluated in the presence of *ssrA* peptide chimeras. As seen in Figure 4b, the ATPase activity of  
170 ClpX was substantially enhanced in *ssrA*<sub>VAA</sub> (mimicking  $\sigma^D$ /RsdA) but was less affected by  
171 *ssrA*<sub>AAA</sub> (mimicking  $\sigma^L$ /RslA) (Figure 4B, Table 3). Finally, we performed an experiment  
172 wherein Green Fluorescent Protein (GFP) chimeras with different degrons at the C-terminus  
173 were subjected to unfolding by ClpX. The degrons in these GFP-chimera substrates mimic those  
174 in the anti- $\sigma$  factors. These results show that GFP<sub>VAA</sub> (mimicking  $\sigma^D$ /RsdA) unfolded faster than  
175 GFP<sub>GAA</sub> (mimicking  $\sigma^M$ /RsmA) or GFP<sub>AAA</sub> (mimicking  $\sigma^K$ /RskA) (Figure 4C, Table A1). As in  
176 the case of the  $\sigma$ /anti- $\sigma$  substrates, GFP<sub>1-8ssrA</sub> (devoid of the last three residues in the degron) was  
177 not unfolded by ClpX. Taken together, the data suggests that degron composition, in particular  
178 the ante-penultimate residue, affects the ATPase and unfoldase activity of *M. tuberculosis* ClpX  
179 (Figure 4A-C).



## 180 **Role of the N-terminal domain of *M. tuberculosis* ClpX in substrate recruitment**

181 Next, we evaluated the role of the N-terminal domain in stabilizing ClpX-substrate interactions.  
182 Towards this ATPase assays were performed with full-length ClpX and the N-terminal deletion  
183 construct of ClpX ( $\Delta$ NCIpX). GFP-degron chimeras were used as substrates in these  
184 experiments. The deletion of the N-terminal domain does not substantially affect ATPase  
185 activity (which is  $\sim 1.2 \mu\text{M}/\text{min}/\mu\text{g}$ , lower than full length ClpX  $\sim 1.4 \mu\text{M}/\text{min}/\mu\text{g}$ ). While ClpX  
186 activity with the full-length enzyme showed a clear degron-dependent gradation- highest in the  
187 case of GFP<sub>VAA</sub> (mimicking  $\sigma^D$ /RsdA) and lowest for GFP<sub>AAA</sub> (mimicking  $\sigma^L$ /RslA), changes in  
188 specific activity of  $\Delta$ NCIpX were less pronounced (Figure 4D, Table 3-4). The unfoldase  
189 activity of  $\Delta$ NCIpX was also monitored for GFP-ssrA chimeras and compared with the activity  
190 of full-length ClpX. Consistent with previous observations, the unfoldase activity of  $\Delta$ NCIpX  
191 was less than ClpX while the degron dependence (GFP<sub>VAA</sub> unfolded faster than GFP<sub>GAA</sub> or  
192 GFP<sub>AAA</sub>) remained unaltered (Figure 4C, Table A1). To determine whether deletion of the N-  
193 terminal domain of ClpX affected the binding affinity with the GFP-degron substrate, we  
194 performed SPR experiments with the  $\Delta$ NCIpX construct. There was a two-fold decrease in the  
195 binding affinity of substrates to  $\Delta$ NCIpX when compared to full-length ClpX (Figure A4, Table  
196 A2). Despite the lower binding affinity for substrate proteins, the  $\Delta$ NCIpX construct retained  
197 degron-dependent gradation- highest in the presence of GFP<sub>VAA</sub> and lowest for GFP<sub>AAA</sub>.

198 ATP binding was shown to stabilise the ClpX hexamer (10). An interesting observation  
199 from these experiments is that ClpX substrate interactions can occur in the absence of  
200 nucleotides. Since this observation stands out from the *E. coli* ClpX system and that the  
201 possibility of the  $\Delta$ NCIpX construct being more unstable than the full-length ClpX persists, we  
202 experimentally evaluated the binding affinity of GFP<sub>VAA</sub> for both ClpX and  $\Delta$ NCIpX in the

203 presence of ATP (Figure A5). Although addition of ATP improved substrate binding for both  
204 ClpX and  $\Delta$ NClpX constructs,  $\Delta$ NClpX bound substrates with lower affinity when compared to  
205 full-length ClpX (Figure A5, Table A3). The N-terminal domain thus influences binding affinity  
206 and the residence time of substrate proteins on ClpX.

## 207 **ClpX links proteostasis with transcription**

208 Under diverse stress conditions, proteolytic degradation of an anti- $\sigma$  factor releases a free  
209 ECF  $\sigma$  factor to bind to the RNA polymerase and initiate transcription. In the case of the *E. coli*  
210 anti- $\sigma$  factor RseA, apart from ClpX, other cellular proteases like ClpAP, Lon and FtsH were  
211 shown to mediate proteolytic degradation (7). *M. tuberculosis* has three Clp-unfoldases- ClpX,  
212 ClpC1 and ClpB. In the case of the cytosolic *M. tuberculosis*  $\sigma^E$ /RseA complex, phosphorylated  
213 RseA was shown to be a target for proteolytic processing by the ClpC1P2P1 assembly (31).  
214 ClpB was shown to be primarily involved in the prevention of heat induced aggregation and  
215 refolding of denatured proteins (32-34). Homologues of the *E. coli* Lon and HslUV proteases  
216 are absent in *M. tuberculosis* (35,36). In the light of these observations, *M. tuberculosis* ClpC1  
217 appeared to be the other likely unfoldase that could participate in anti- $\sigma$  factor degradation.  
218 Experiments performed with freshly purified *M. tuberculosis* ClpXP2P1 and ClpC1P2P1  
219 complexes reveal that  $\sigma^D$ /RsdA is proteolysed specifically by the ClpXP2P1 and not by the  
220 ClpC1P2P1 complex (Figure 5A).

221 To evaluate if expression levels of *clpX* and the anti- $\sigma$  factor genes were correlated, gene  
222 expression microarray datasets from different experimental conditions like hypoxia, stationary  
223 phase, oxidative stress and presence of Vitamin C were examined (compiled in Table 5). While  
224  $\sigma^D$  maintains homeostasis in the late stationary phase of *M. tuberculosis* growth, genes in the  $\sigma^M$

225 regulon express in the stationary phase (37,38). The oxidative stress response involves both  $\sigma^K$   
226 and  $\sigma^L$  as these ECF  $\sigma$  factors together respond to redox stress stimuli (27,28). The genes  
227 encoding for each *M. tuberculosis*  $\sigma$  and anti- $\sigma$  factor pairs examined in this study lie in the same  
228 operon, and are positively regulated by the cognate  $\sigma$  factor. Despite multiple other factors that  
229 could influence gene expression, we note a correlation between the expression level of *clpX* and  
230 anti- $\sigma$  factor genes in specific environmental conditions (Table 5). This finding was further  
231 evaluated in an experiment wherein the mRNA levels of the different  $\sigma$  factors were monitored  
232 upon *clpX* induction by quantitative real-time PCR (qPCR). The premise for this experiment  
233 was that increasing ClpX levels would result in more degradation of the target anti- $\sigma$  factor  
234 thereby enhancing the cellular abundance of the corresponding free ECF  $\sigma$ 's. An increase in the  
235 intracellular levels of ECF  $\sigma$ 's, in turn, would result in upregulation of genes in the  
236 corresponding regulon. This hypothesis was examined in two experimental conditions in *M.*  
237 *tuberculosis* H37Rv- at the logarithmic phase and late stationary phase of growth. The stationary  
238 phase, in particular, was evaluated as RsdA (anti- $\sigma^D$ ) shows the highest susceptibility for ClpX  
239 induced proteolysis *in vitro* and  $\sigma^D$  was shown to maintain homeostasis in the late stationary  
240 phase of *M. tuberculosis* growth (39). We note that the expression levels of  $\sigma^D$  are most  
241 upregulated upon ClpX induction in both experimental conditions (Figure 5B, A5). On the other  
242 hand, the mRNA levels of *sigL* were relatively unaffected upon *clpX* induction. Thus increased  
243 levels of ClpX directly influence the intracellular concentration of free  $\sigma$  factors. We note that  
244 under logarithmic growth phase (in which the anti- $\sigma$  factor is less susceptible to RIP proteolysis)  
245 the effect is less pronounced (Figure A6, A7).

246 In an effort to evaluate down-stream effects of changes in  $\sigma$  factor levels, the mRNA  
247 levels of representative genes from the regulons of *sigD*, *sigM*, *sigK* and *sigL* were examined by

248 qPCR in the late stationary phase (40-42). These experiments reveal that (i) The expression of  
249 all four ECF  $\sigma$  factors is upregulated upon ClpX induction and (ii) Upregulation of the cognate  
250 regulon is less clear (Figure 6A). Some aspects of the non-linear response upon ClpX induction  
251 can be rationalized, however. For example, while RskA and RslA share the same degron  
252 sequence (AAA), the expression of *sigK* (and *rskA*) is higher than *sigL* (and *rsIA*). Another  
253 feature that could contribute to non-linearity is that the release of  $\sigma^K$  from the  $\sigma^K$ /RskA complex  
254 is also governed by redox stimuli-  $\sigma^K$  is a redox sensor allowing dissociation of RskA under  
255 reducing conditions (28). It thus appears likely that differences in the expression of the  $\sigma^K$   
256 regulon are likely to mimic steady state levels in stationary phase, low oxygen *M. tuberculosis*  
257 cultures (43). Another parameter that could significantly influence this experiment is that ClpX  
258 dependence is preceded by RIP-1 activity on the anti- $\sigma$  factor in the Regulated Intramembrane  
259 Proteolysis (RIP) pathway. RIP-1 activity is also influenced by environmental stimuli (6).  
260 Taken together, these observations suggest that ClpX activity alters intracellular ECF  $\sigma$  factor  
261 levels in a degron-dependent manner thereby influencing the expression profile in *M.*  
262 *tuberculosis* (Figure 6B).

## 263 Discussion


264 An intriguing feature in ECF  $\sigma$  factors, examined extensively in *E. coli* and *B. subtilis*, is  
265 that of overlapping regulons (44-47). This overlap in  $\sigma$  factor function ensures appropriate  
266 changes to the transcriptional profile - wherein multiple ECF  $\sigma$ 's are activated upon a stress  
267 signal (48). Another aspect is the apparent hierarchy amongst  $\sigma$  factors. Some  $\sigma$  factors (*M.*  
268 *tuberculosis*  $\sigma^C$  or  $\sigma^I$ , for example) are under the control of  $\sigma^F$  which, in turn, is regulated by  $\sigma^M$   
269 (49,50). Both these aspects depend on the cellular concentration of ECF  $\sigma$ 's which is largely  
270 regulated by a post-translational mechanism involving the release of free  $\sigma$  factor from an

271 inactive  $\sigma$ /anti- $\sigma$  complex (51). These release mechanisms either involve concerted  
272 conformational changes leading to the dissociation of the inactive  $\sigma$ /anti- $\sigma$  complex or targeted  
273 proteolysis of the anti- $\sigma$  to release the free ECF  $\sigma$ . Targeted proteolysis based on an accessible  
274 degron in a substrate effectively controls cellular protein levels. Indeed, this strategy is  
275 considered robust enough to be employed for optimizing microbial cell factories for diverse  
276 applications (52). It is in this context that the finding that the *M. tuberculosis* ClpX activity is  
277 modulated by degron composition becomes relevant.

278 In the Regulated Intramembrane Proteolysis (RIP) cascade, the signal transduction of  
279 environmental stress to the transcription mechanism has multiple temporal checkpoints- (i) the  
280 rate at which the extra-cytoplasmic receptor domain responds to the stress stimulus (ii) the rate  
281 of trans-membrane signal transduction involving the site-1 protease(s) and the site-2 protease  
282 Rip1 that acts on all membrane associated anti- $\sigma$ 's (iii) the rate at which the anti- $\sigma$  domain is  
283 selectively degraded by ClpX to release the free ECF  $\sigma$  to initiate transcription. In the *E. coli*  
284 RIP cascade, the proteolytic step initiated by the site-1 protease DegS is the rate limiting step  
285 ( $T_{1/2} \leq 1$  min) for RseA degradation, with the other two proteolytic events being at least three-fold  
286 faster (7). The dissociation of RseA from the membrane generates a cytosolic fragment with a  
287 degron (sequence ending in VAA) (8). The specific degradation of the cytosolic RseA by ClpXP  
288 is rapid ( $T_{1/2} \leq 20$  sec) and aided by an adaptor, SspB (7, 8). In the event ClpXP is weighed down  
289 by competing substrates, other cellular proteases can take over, albeit at a slower rate ( $T_{1/2} \leq 1.6$   
290 min). Thus DegS activity on RseA is the rate-limiting step in the *E. coli* RIP pathway governing  
291 the cellular levels of  $\sigma^E$  (7). While *E. coli* RseA is potentially a substrate for multiple proteases  
292 like ClpA, HslUV, and Lon, ClpXP was demonstrated to be the major proteolytic complex in this

293 process. It is worth noting in this context that *E. coli* *clpX* and *clpP* are not essential (53). On  
294 the other hand, *M. tuberculosis* *clpX*, *clpP1* and *clpP2* are essential genes (37,54).

295 The ability of *M. tuberculosis* ClpX to bind substrates in the absence of ATP suggested  
296 *M. tuberculosis* ClpX alternates between two different states, an observation similar to Hsp60  
297 and Hsp70 chaperones (55). *E. coli* ClpX has also been shown to switch between two  
298 conformations- an ‘open state’ with lower binding affinity for substrates in the absence of  
299 nucleotides and a ‘closed state’ with higher affinity in response to ATP binding and hydrolysis  
300 (56). The finding that variations in substrate interaction kinetics elicited correlated changes in  
301 unfoldase activity suggested that concerted conformational changes could be a prominent feature  
302 of adaptor-independent ClpX activity. Indeed, in *E. coli*, conformational changes in AAA+  
303 proteases were shown to provide a mechanism to correlate ATP hydrolysis with denaturation of  
304 target protein substrates (10). ATPase assays and SPR interaction studies performed with both  
305 wild-type ClpX and  $\Delta$ NClpX suggest that the N-terminal domain plays a role in substrate  
306 recruitment by affecting both ATPase activity as well as substrate binding in ClpX. The  
307 correlation between interaction kinetics (monitored by Surface Plasmon Resonance) and ATPase  
308 activity was significantly dampened in  $\Delta$ NClpX when compared to full-length ClpX. This  
309 observation that interaction kinetics obtained from SPR experiments are consistent with both  
310 ATPase activity and unfoldase assays (significant differences only in the presence of cognate  
311 substrates) suggests that non-specific interactions are unlikely. On the other hand, the  
312 observation that dissociation trajectories of substrates do not return to the baseline indicate a  
313 slow dissociation process- as aspect that has been reported earlier in the case of *E. coli* ClpX. A  
314 plausible rationale for this comes from the low frequency Normal Modes in the *M. tuberculosis*  
315 ClpX model that suggests flexible tethering of the NTD in ClpX could enable conformational  
316 changes for stronger substrate interactions (Figure A3). This finding is similar to *E. coli* ClpX  
317 wherein nucleotide-dependent movements of the NTD facilitate the entry of substrates inside the  
318 ClpX ring (57). Put together, these data are consistent with an induced fit model for ClpX that  
319 can be described as-



320

321 where  $k_1$  is the rate at which substrate binds,  $k_2$  and  $k_2$  are the relative rates of conformational  
322 changes induced by substrate binding in the forward and backward directions,  $k_3$  is the rate of  
323 chemical reaction and  $k_4$  is the rate of product release. ‘o’ and ‘c’ stand for the open (before  
324 conformational change) and closed (after conformational change) states of the enzyme. The  
325 increase in ATPase activity upon *E. coli* ClpX interaction with a substrate was shown to precede  
326 a series of conformational changes in this enzyme (58,59). These transitions were seen to initiate  
327 conformational changes in the pore-1 (GYVG) and pore-2 (RKSENPSITRD) loops to accelerate  
328 ATP hydrolysis (58, 59). With a favourable amino acid at the ante-penultimate position,  
329 conformational changes engage the substrate and the enzyme switches from an open to closed  
330 state leading to increased ATPase activity and the consequent unfolding of the substrate. When  
331  $k_2$  becomes  $\llll k_3$ , the substrate is committed for the reaction after the conformational change.  
332 The observation that ATPase activity of  $\Delta\text{NClpX}$  is less than full-length ClpX agrees well with  
333 the above model (Figure 4D, Table 3-4).

334 The finding that the last step in the RIP proteolytic cascade involving *M. tuberculosis*  
335 ClpX varies across substrates- fastest for RsdA and slowest for RslA- suggests significant  
336 differences from the *E. coli* model. In *E. coli*, the expression of the  $\sigma^E$  regulon in *clpX* and *sspB*  
337 null mutants is reduced- suggesting a correlation between proteolysis and transcription (8). The  
338 presence of multiple anti- $\sigma$ 's in *M. tuberculosis* and degron-dependent variations in ClpX  
339 unfolding suggests a broader application of this link between targeted protein degradation and  
340 the expression profile. Previous reports on *sigA* transcript levels in *M. tuberculosis* H37Rv

341 suggest that *sigA* expression is not altered at different phases of growth and exposure to stresses  
342 *in vitro* (44,60,61). However, upon ClpX overexpression, we observe differences in the levels of  
343 *sigA*- these are lower in the stationary phase than the logarithmic phase (Figure A8).  $\sigma^A$   
344 modulates the expression of essential genes and virulence in *M. tuberculosis* (60). ClpX over-  
345 expression is thus likely to affect the ability of *M. tuberculosis* H37Rv to respond to stress. The  
346 degraon-dependent differences in ClpX-anti- $\sigma$  interactions and subsequent release of free ECF  $\sigma$ 's  
347 from the inactive complex is thus expected to lead to a measured change in transcription in  
348 response to a stress signal in *M. tuberculosis* (Figure 7A-B). An analysis using annotated  $\sigma$ /anti-  
349  $\sigma$  pairs suggests that this feature is likely to be applicable in other bacteria (62). Indeed, a large  
350 proportion of ECF anti- $\sigma$  factor sequences having one transmembrane helix (similar to the *M.*  
351 *tuberculosis* membrane associated anti- $\sigma$ 's) have a *ssrA*-like degraon (567 of 722 anti- $\sigma$  factors)  
352 (Figure 1B). Put together, these data suggest that the *M. tuberculosis* ClpX function is more  
353 nuanced than a simple on/off switch in releasing ECF  $\sigma$  factors from an inactive  $\sigma$ /anti- $\sigma$   
354 complex. It appears likely that this variation in the unfoldase activity of ClpX is, in effect, a  
355 regulatory layer coordinating environmental stimuli to elicit calibrated changes in gene  
356 expression.

357

## 358 **Materials and Methods**

### 359 **Cloning, expression and purification of recombinant proteins**

360 *M. tuberculosis* *clpX*, *clpC1*, *clpP2* genes were cloned in the *E. coli* expression vector pET28a  
361 while *clpP1* was cloned in the MCS1 of the pETDuet-1 vector (Novagen, Inc.). In case of the  
362  $\sigma$ /anti- $\sigma$  factor complex substrates, the full length  $\sigma$  factors ( $\sigma^D$ ,  $\sigma^K$ ,  $\sigma^L$  and  $\sigma^M$ ) were cloned in



363 the multiple cloning site I (MCS-I), whereas the anti- $\sigma$  factor constructs (ending at the *ssrA*-like  
364 motif at the C-terminal end), were cloned in the MCS-II of pETDuet-1 expression vector. GFP-  
365 *ssrA* from *E. coli* was obtained as a gift from Prof. Tania Baker's laboratory. Mutants for the  
366  $\sigma$ /anti- $\sigma$  substrates and the GFP-*ssrA* mutants were prepared following standard Site-directed  
367 Mutagenesis (SDM) protocol (Table A4 lists the details of the constructs used in this study). The  
368 plasmids were transformed into a ClpP knockout strain of *E. coli* (obtained from Prof. Tania  
369 Baker's laboratory). *E. coli* cultures were grown in Luria broth with appropriate antibiotic  
370 markers, to an optical density (O.D.<sub>600</sub>) of 0.4-0.6 at 37°C, whereupon they were induced with  
371 0.8mM isopropyl- $\beta$ -D-1-thiogalactopyranoside (IPTG). Post induction, the cells were grown at  
372 a temperature of 18°C for 12-14 hours and harvested by centrifugation at 4500 rpm. The pellet  
373 for Clp-proteins was re-suspended and sonicated in lysis buffer (buffer L) containing 50mM  
374 Tris-HCl pH 7.6, 300mM NaCl, 100mM KCl, 1mM DTT, 10mM imidazole and 10% v/v  
375 glycerol, while the cell pellet for the  $\sigma$ /anti- $\sigma$  factor complexes were re-suspended in buffer L  
376 devoid of DTT (except for the  $\sigma^L$ /RslA complex). After sonication, the cell debris was separated  
377 from the crude cell lysate by centrifugation for 30 min at 15000 rpm. The cell-free lysate was  
378 then incubated with Ni<sup>2+</sup>-Nickel-nitrilotriacetic acid (NTA) affinity beads (Sigma-Aldrich, Inc.)  
379 for 1 hour at 4°C. The bound proteins were eluted by a gradient of imidazole concentration  
380 (50mM to 250mM) prepared in buffer L. The pure fractions were pooled, concentrated and  
381 loaded on to a PD-10 desalting column (GE Healthcare) and were desalted in buffer D (50mM  
382 HEPES-KOH pH 7.5, 25mM MgCl<sub>2</sub>, 100mM KCl, 0.1mM EDTA and 10% v/v glycerol) for  
383 Clp-proteins, and buffer S (50mM HEPES-KOH, pH 7.5, 100mM KCl and 10% v/v glycerol) for  
384 the substrate proteins.

### 385 **Surface Plasmon Resonance**

386 Interaction studies were performed on a BIACORE 2000 instrument (Biacore, Uppsala,  
387 Sweden). ClpX was covalently immobilized on a CM5 sensor chip (Biacore) using standardized  
388 protocol in replicates. The SPR buffer (50mM HEPES, 200mM KCl with 10% Glycerol at pH  
389 7.5) filtered through 0.45 micron membrane filters (Millipore) and degassed was used in these  
390 experiments. Experiments were carried out at 25°C. Carboxymethyl groups on the chip were  
391 activated by injecting freshly prepared Ethyl-3-(3-dimethylaminopropyl)-carbodiimide/ N-  
392 Hydroxysuccinimide (EDC/NHS: 1M each) mixture (1:1). ClpX diluted in 10mM Sodium  
393 acetate (pH 4.0) was then passed over the active surface till required immobilization was  
394 achieved. The un-reacted activated sites were blocked with 1M Ethanolamine. 50  $\mu$ l (flow rate:  
395 30 $\mu$ l/min) of each substrate at various concentrations were passed over the flow cells and  
396 allowed to dissociate for 200 seconds. The sensor surface was regenerated using multiple  
397 injections of 4M MgCl<sub>2</sub> and/or 0.05-0.1% SDS whenever required. The reference subtracted  
398 response curves obtained for substrate binding to ClpX were evaluated using BIA evaluation  
399 software. The data obtained was fit to Langmuir 1:1 interaction model to obtain rates of  
400 association ( $k_a$ ) and dissociation ( $k_d$ ). Standard deviation across replicates was used to calculate  
401 the fitting error (Table A5, Figure A2) (63,64). The equilibrium dissociation constant ( $K_D$ ) is  
402 defined as the ratio of the dissociation rate constant ( $k_d$ ) and the association rate constant ( $k_a$ ).

403

404

#### 405 **ATPase assay**

406 ATPase assays were performed using malachite green to calculate the specific activity of ClpX.

407 The assays were performed with 100nM ClpX and 5 $\mu$ M of substrate protein or 20 $\mu$ M of ssrA

408 peptides in buffer containing 25 mM HEPES (pH 7.6), 200 mM KCl, 20 mM MgCl<sub>2</sub>, 10%  
409 glycerol. The reaction was initiated by the addition of 1mM ATP and was carried out at 30°C  
410 for 25mins. Malachite green dye buffer containing 0.045% malachite green, 4.2% ammonium  
411 molybdate and 1% Triton X-100 was added to the reaction mixture at suitable time points. After  
412 1 min, 34% citric acid was added to the reaction mixture, mixed well and further incubated for  
413 40mins for colour development. Absorbance was measured at 660nm. The inorganic phosphate  
414 released was calculated based on the absorbance standard curve established by H<sub>3</sub>PO<sub>4</sub> standards.

#### 415 **Unfoldase Assay**

416 The catalytic unfolding of GFP<sub>ssrA</sub> substrate by ClpX was monitored using an identical  
417 experimental protocol as in the case of *E. coli* ClpX (56). Unfolding of GFP<sub>ssrA</sub> was monitored  
418 using a Varioskan plate reader with an excitation wavelength of 488nm and emission wavelength  
419 of 520nm. The reaction was monitored over a period of 30 minutes (Figure A9). The reaction  
420 mixture comprised of 1X Unfoldase buffer (25mM HEPES pH 7.5, 20mM MgCl<sub>2</sub>, 10%  
421 glycerol), 1X ATP regeneration system (Creatine Phosphate (16mM) and Creatine Kinase  
422 (0.32mg/ml), 200mM KCl, 100nM ClpX and 5uM of GFP<sub>ssrA</sub> substrate.

#### 423 **Molecular modelling and Normal Modes Analysis**

424 The molecular model for *M. tuberculosis* ClpX was constructed using Modeller (65). The crystal  
425 structure of *E. coli* ClpX (3HWS) was used as template for comparative modelling. In this  
426 procedure, care was taken to ensure that the asymmetry observed in the ClpX hexamer was  
427 retained in the energy minimised model. Both the C and F chains of the obtained model had the  
428 closed conformation as observed in the *E. coli* ClpX crystal structure. Molecular graphics,  
429 energy minimisation of the model and analyses were performed with the UCSF Chimera package

430 (66). Normal Modes Analysis was performed using Anisotropic Network Model Web Server 2.1  
431 (67).

### 432 **RNA isolation and qPCR analysis**

433 *M. tuberculosis* H37Rv transformed with pNit-3F vector and pNit-3F-ClpX were grown in the  
434 presence of 5  $\mu$ M Isovaleronitrile (IVN) as inducer. 10 ml of bacterial cells at O.D.<sub>600</sub> ~1.0 were  
435 processed to extract RNA using the Trizol method. Briefly, cells were lysed in 1 ml Trizol using  
436 three cycles of 30s bead-beating with intermittent ice treatment for two minutes. The cell debris  
437 was removed from the lysate by centrifugation at 13,000 rpm for 10 minutes. The lysate was  
438 treated with 400  $\mu$ l chloroform and centrifuged to separate the three phases. The top layer  
439 containing RNA was carefully extracted and the RNA was precipitated by addition of 1 ml  
440 isopropanol. The RNA pellet thus obtained was washed with 70% ethanol to remove excess  
441 salts. The dried RNA pellet was dissolved in 30 $\mu$ l RNase free water and kept overnight at 4°C to  
442 ensure complete dissolution. The RNA was quantified using NanoDrop (Thermo Scientific™  
443 NanoDrop 2000c) and the sample was run on a 1% formaldehyde-agarose gel to estimate  
444 integrity. RNA sample was further processed by passing through RNeasy mini column (Qiagen).  
445 1 $\mu$ g of purified RNA of each test and control sample was then treated with DNaseI (Thermo  
446 Scientific, Inc) to remove contaminating DNA and was used for cDNA synthesis employing one  
447 step-cDNA synthesis kit from Biorad (Biorad, Inc.). The cDNA synthesis was performed in  
448 20 $\mu$ l reaction mixtures as per manufacturers' protocol using 500ng of pure DNaseI treated RNA  
449 as template. Minus reverse transcriptase reaction was processed simultaneously as a control.  
450 For final qPCR reactions, the 20  $\mu$ l of cDNA reaction mix was diluted to 100  $\mu$ l and 2 $\mu$ l was  
451 utilised as template per reaction. Oligonucleotide sequences for qPCR were designed using  
452 'Primer 3' software (Table A6 lists primers, T<sub>m</sub> and the GC content of primers used). 16s rRNA

453 amplicon was used as reference gene. Two-step SYBR green PCR reactions were performed in  
454 MasterCycler RealPlex4 (Eppendorf, Germany) machine as 10ul reactions in triplicates. The  
455 following conditions were used for amplification with SYBR green- 10 minutes at 95°C  
456 followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Melt curve analysis was  
457 done for each primer pair. Reverse transcriptase minus and plus cDNA samples were subjected  
458 to qPCR with 16s rRNA primers for analysis of gDNA contamination. For each individual gene  
459 analysed using qPCR, the  $C_q$  values were normalized with respect to  $C_q$  values of 16s rRNA  
460 amplicon. After normalization of  $C_q$  values, the fold change in the expression of various genes  
461 upon ClpX over-expression was calculated by  $2^{(-\Delta\Delta C_t)}$  method as described previously. Relative  
462 quantification allowed us to relate the PCR signal of our target transcripts in ClpX over-  
463 expressed group to that of the Vector control (V.C.) group. The  $2^{(-\Delta\Delta C_t)}$  method was used to  
464 analyze the relative changes in gene expression (68).

#### 465 **Protease assays**

466 The assays were performed in buffer containing 50 mM HEPES–KOH (pH 7.5), 150 mM KCl,  
467 20 mM MgCl<sub>2</sub> and 10% glycerol at 37°C. Clp proteases ClpP2 and ClpP1 (1μM each) were pre-  
468 incubated with 0.1mM Z-LL di-peptide for 30 minutes at 37°C. This step was followed by the  
469 pre-incubation of ClpC1 or ClpX (0.5 μM), ClpP2P1 (1μM),  $\sigma^D$ /RsdA<sub>VAA</sub> substrate (5.0  
470 μM)/PyrB (1uM) substrate and an ATP-regeneration system (0.32 mg/ml Creatine kinase and 16  
471 mM Creatine phosphate) for 10 minutes to allow formation of stable ClpXP2P1 or ClpC1P2P1  
472 complexes. The reaction was initiated by the addition of 5mM ATP. Samples were removed  
473 after specific time intervals and a western blot was performed using anti-RsdA and anti- $\sigma^D$   
474 antibodies at 1:7000 dilution while ClpX, the Clp-proteases (ClpP2 and ClpP1) and PyrB were  
475 probed with anti-Histidine monoclonal antibodies (GE Healthcare) at 1:10,000 dilution.

476 Immunoblots were developed with Luminata<sup>TM</sup> Forte Western HRP substrate for peroxidase-  
477 attached secondary antibodies.

#### 478 **Expression levels and Correlation analysis**

479 The expression levels of *clpX* and the four *anti-sigma* genes were obtained from previously  
480 published micro-array datasets (GSE16146, GSE101048 and GSE8786). Each dataset  
481 corresponds to different experimental conditions; Logarithmic phase (N=3), Stationary phase  
482 (N=3), Hypoxia (N=3), Oxidative Stress (Reactive Oxygen Species (R.O.S), N=3), Vitamin C  
483 (N=3). Pearson's correlation coefficients and t values (Student's t test) between a given *anti-σ*  
484 factor and *clpX* were calculated in all experimental conditions using the formula given below:

$$r = (\Sigma(x - xi)(y - yi)) / (\sqrt{(\Sigma(x - xi)^2 \Sigma(y - yi)^2)})$$

485  $t=r / (1-(0.92^2))^{0.5}$  (r= correlation coefficient).

486

#### 487 **Acknowledgements**

488 We thank Ms. Shanta Sen and Mass spectrometry facility of National Institute of Immunology  
489 for mass spectrometry studies and Sneha Vishwanath, Himani Tandon for their help in  
490 computational studies. We thank Dr. Sess, Savitha N and Vandana and Ashish Deshmukh. We  
491 also thank Mrs. Sreelatha for her help with the SPR studies and Dr. Vinothkumar Kutti for his  
492 valuable comments on the manuscript.

#### 493 **Author Contributions**

494 ACJ, VKN and BG were involved in the design of this study. ACJ, PK, RKN, DSL were  
495 involved in data acquisition and analysis. ACJ, VKN and BG wrote the manuscript.

496 **Declaration of Interests**

497 The authors declare no competing interests.

498

## 499 **References**

1. Stallings CL, Glickman MS. 2010. Is *Mycobacterium tuberculosis* stressed out? A critical assessment of the genetic evidence. *Microbes Infect.*, 12(14-15), 1091–1101.
2. Helmann JD. 2002. The extracytoplasmic function (ECF) sigma factors. *Adv Microb Physiol.*, 46, 47-110.
3. Rodrigue S, Provvedi R, Jacques PE, Gaudreau L, Manganelli R. 2006. The sigma factors of *Mycobacterium tuberculosis*. *FEMS Microbiol. Rev.*, 30, 926-941.
4. Sachdeva P, Misra R, Tyagi AK, Singh Y. 2009. The sigma factors of *Mycobacterium tuberculosis*: regulation of the regulators, *FEBS J.*, 277, 605-626.
5. Gruber TM, Gross CA. 2003. Multiple sigma subunits and the partitioning of bacterial transcription space. *Annu. Rev. Microbiol.*, 57, 441–466.
6. Heinrich J, Wiegert T. 2009. Regulated intramembrane proteolysis in the control of extracytoplasmic function sigma factors. *Res. Microbiol.*, 160, 696–703.
7. Chaba R, Grigorova IL, Flynn JM, Baker TA, Gross CA. 2007. Design principles of the proteolytic cascade governing the  $\sigma^E$ -mediated envelope stress response in *Escherichia coli*: keys to graded, buffered, and rapid signal transduction. *Genes Dev.*, 21, 124–136.
8. Flynn JM, Levchenko I, Sauer RT, Baker TA. 2004. Modulating substrate choice: the SspB adaptor delivers a regulator of the extracytoplasmic-stress response to the AAA+ protease ClpXP for degradation. *Genes & Dev.*, 18, 2292-2301.
9. Flynn JM, Levchenko I, Seidel M, Wickner SH, Sauer RT, Baker TA. 2001. Overlapping recognition determinants within the *ssrA* degradation tag allow modulation of proteolysis. *Proc Natl Acad Sci. USA*, 98(19), 10584-10589.
10. Sauer RT, Baker TA. 2012. ClpXP, an ATP-powered unfolding and protein-degradation machine. *Biochem Biophys. Acta.*, 1823(1), 15-28.



11. Mahmoud SA and Chien P. 2018, Regulated Proteolysis in Bacteria. *Annu. Rev. Biochem.* 87, 677-696.
12. Dougan DA, Mogk A, Zeth K, Turgay K, Bukau B. 2002. AAA+ proteins and substrate recognition, it all depends on their partner in crime. *FEBS Lett.*, 529, 6-10.
13. Neher SB, Sauer RT, Baker TA. 2003. Distinct peptide signals in the UmuD and UmuD' subunits of UmuD/D' mediate tethering and substrate processing by the ClpXP protease. *Proc Natl Acad Sci U S A.*, 100, 13219–13224.
14. Miller JM, Enemark EJ. 2016. Fundamental Characteristics of AAA+ Protein Family Structure and Function. *Archaea*, Vol.2016, Article ID 9294307, 12 pages.
15. Wojtyra UA, Thibault G, Tuite A, Houry WA. 2003. The N-terminal Zinc Binding Domain of ClpX Is a Dimerization Domain That Modulates the Chaperone Function. *J Biol Chem.*, 278(49), 48981-48990.
16. Donaldson LW, Wojtyra U, Houry WA. 2003. Solution Structure of the Dimeric Zinc Binding Domain of the Chaperone ClpX. *J Biol Chem.*, 278(49), 48991-48996.
17. Glynn SE, Martin A, Nager AR, Baker TA, Sauer RT. 2009. Structures of Asymmetric ClpX Hexamers Reveal Nucleotide-Dependent Motions in a AAA+ Protein-Unfolding Machine. *CELL.*, 139(4), 744–756.
18. Hanson PI, Whiteheart SW. 2005. AAA+ Proteins: Have Engine, Will Work. *Nat Rev Mol Cell Biol.*, 6(7), 519-529.
19. Flynn JM, Neher SB, Kim YI, Sauer RT, Baker TA. 2003. Proteomic discovery of cellular substrates of the ClpXP protease reveals five classes of ClpX-recognition signals. *Mol Cell.*, 11(3), 671-683.
20. Sklar JG, Makinoshima H, Schneider JS, Glickman MS. 2010. *M. tuberculosis* intramembrane protease Rip1 controls transcription through three anti-sigma factor substrates. *Mol Microbiol.*, 77(3), 605-617.

21. Schneider JS, Sklar JG, Glickman MS. 2014. The Rip1 Protease of *Mycobacterium tuberculosis* Controls the SigD Regulon. *J Bacteriol.*, 196(14), 2638-2645.
22. Alba BM, Leeds JA, Onufryk C, Lu CZ, Gross CA. 2002. DegS and YaeL participate sequentially in the cleavage of RseA to activate the sigma(E)-dependent extracytoplasmic stress response. *Genes Dev.* 16(16), 2156-68.
23. Kanehara K, Ito K, Akiyama Y. 2002. YaeL (EcfE) activates the sigma(E) pathway of stress response through a site-2 cleavage of anti-sigma(E), RseA. *Genes Dev.* 16(16), 2147-55.
24. Heinrich J, Hein K and Wiegert T 2009. Two proteolytic modules are involved in regulated intramembrane proteolysis of *Bacillus subtilis* RsiW. *Mol. Microbiol.*, 74, 1412–1426.
25. Raju RM, Unnikrishnan M, Rubin DHF, Krishnamoorthy V, Kandror O, Akopian TN, Goldberg AL, Rubin EJ. 2012. *Mycobacterium tuberculosis* ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in Vitro and during Infection. *PloS Pathog.*, 8(2), e1002511.
26. Jaiswal RK, Prabha TS, Manjeera G, Gopal B. 2013. *Mycobacterium tuberculosis* RsdA provides a conformational rationale for selective regulation of  $\sigma$ -factor activity by proteolysis. *Nucleic Acids Res.* 41(5), 3414-3423.
27. Thakur KG, Praveena T, Gopal B. 2010. Structural and Biochemical Bases for the Redox Sensitivity of *Mycobacterium tuberculosis* RslA. *J. Mol.Biol.*,397(5), 1199–1208.
28. Shukla J, Gupta R, Thakur KG, Gokhale R, Gopal B. 2014. Structural basis for the redox sensitivity of the *Mycobacterium tuberculosis* SigK-RskA  $\sigma$ -anti- $\sigma$  complex. *ActaCrystallogr D.*, 70, 1026-1036.
29. Thakur KG, Jaiswal RK, Shukla JK, Praveena T, Gopal B. 2010. Over-expression and purification strategies for recombinant multi-protein oligomers: A case study of *Mycobacterium tuberculosis*  $\sigma$ /anti- $\sigma$  factor protein complexes. *Prot. Exp. Purif.*, 74(2), 223-230.
30. Burton RE, Baker TA, Sauer RT. 2003. Energy-dependent degradation: Linkage between ClpX-catalyzed nucleotide hydrolysis and protein-substrate processing. *Protein Sci.*, 12(5), 893–902.

31. Barik S, Sureka K, Mukherjee P, Basu J, Kundu M. 2010. RseA, the SigE specific anti-sigma factor of *Mycobacterium tuberculosis*, is inactivated by phosphorylation-dependent ClpC1P2 proteolysis. *Mol. Microbiol.*, 75, 592-606.
32. Goloubinoff P, Mogk A, Zvi AP, Tomoyasu T, Bukau B. 1999. Sequential mechanism of solubilization and refolding of stable protein aggregates by a chaperone network. *Proc Natl Acad Sci USA.*, 96, 13732–13737.
33. Mogk A, Tomoyasu T, Goloubinoff P, Rudiger S, Roder D, Langen H, Bukau B. 1999. Identification of thermolabile *Escherichia coli* proteins: prevention and reversion of aggregation by DnaK and ClpB. *EMBO J.*, 18, 6934–6949.
34. Motohashi K, Watanabe Y, Yohda M, Yoshida M. 1999. Heat-inactivated proteins are rescued by the DnaK·J-GrpE set and ClpB chaperones. *Proc Natl Acad Sci USA.*, 96, 7184–7189.
35. Bajaj D, Batra JK. 2012. The C-terminus of ClpC1 of *Mycobacterium tuberculosis* is crucial for its oligomerization and function. *PLoS One.*, 7, e51261.
36. Laederach J, Leodolter J, Warweg J, Weber-Ban E. 2014.. Chaperone-Proteases of Mycobacteria. In Houry, W. (ed.), *The Molecular Chaperones Interaction Networks in Protein Folding and Degradation* (pp. 445–481). Springer, New York.
37. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. *Mol Microbiol.*, 48, 77–84.
38. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol Microbiol.* 43(3), 717–731.
39. Calamita H, Ko C, Tyagi S, Yoshimatsu T, Morrison N.E, Bishai W.R. 2004. The *Mycobacterium tuberculosis* SigD sigma factor controls the expression of ribosome-associated gene products in stationary phase and is required for full virulence. *Cell Microbiol.*; 7:233–244.

40. Raman S, Hazra R, Dascher CC, Husson RN. 2004. Transcription Regulation by the *Mycobacterium tuberculosis* Alternative Sigma Factor SigD and Its Role in Virulence. *J. Bacteriol.*, 186 (99), 6605-6616.
41. Hahn M, Raman S, Anaya M, Husson RN. 2005. The *Mycobacterium tuberculosis* Extracytoplasmic-Function Sigma Factor SigL Regulates Polyketide Synthases and Secreted or Membrane Proteins and Is Required for Virulence. *J. Bacteriol.*, 187 (20), 7062-7071.
42. Veyrier F, Saïd-Salim B, Behr MA. 2008. Evolution of the Mycobacterial SigK Regulon. *J. Bacteriol.*, 190 (6), 1891-1899.
43. Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE, III, Andersen P. 2002. Hypoxic response of *Mycobacterium tuberculosis* studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. *J Bacteriol.*, 184:3485–3491.
44. Wade JT, Castro Roa D, Grainger DC., Hurd D, Busby SJ, Struhl K, Nudler E. 2006. Extensive functional overlap between sigma factors in *Escherichia coli*. *Nat Struct Mol Biol.*, 13(9), 806-814.
45. Luo Y, Helmann JD. 2009. Extracytoplasmic function sigma factors with overlapping promoter specificity regulate sublancin production in *Bacillus subtilis*. *J. Bacteriol.*, 191, 4951–4958.
46. Cao M, Helmann JD. 2002. Regulation of the *Bacillus subtilis* bcrC bacitracin resistance gene by two extracytoplasmic function sigma factors. *J Bacteriol.*, 184(22), 6123-6129.
47. Huang X, Fredrick KL, Helmann JD. 1998. Promoter recognition by *Bacillus subtilis* sigmaW: autoregulation and partial overlap with the sigmaX regulon. *J Bacteriol.*, 180(15), 3765-3770.
48. Manganelli R, Dubnau E, Tyagi S, Kramer FR and Smith I. 1999. Differential expression of 10 sigma factor genes in *Mycobacterium tuberculosis*. *Mol. Microbiol.*, 31, 715–724.
49. Chauhan R, Ravi J, Datta P, Chen T, Schnappinger D, Bassler KE, Balazsi G, Gennaro ML. 2015. Reconstruction and topological characterization of the sigma factor regulatory network of *Mycobacterium tuberculosis*. *Nat. Commun.*, 7, 11062.

50. Bervoets I, van Brempt M, van Nerom K, van Hove B, Maertens J, de Mey M, Charlier D. 2018. A sigma factor toolbox for orthogonal gene expression in *Escherichia coli*. *Nucleic Acids Res.*, 46(4), 2133–2144.
51. Campbell EA, Westblade LF, Darst SA. 2008. Regulation of bacterial RNA polymerase  $\sigma$  factor activity: a structural perspective. *Curr Opin Microbiol.*, 11, 121–127.
52. Landry BP, Stöckel J, Pakrasi HB. 2013. Use of Degradation Tags To Control Protein Levels in the Cyanobacterium *Synechocystis sp.* Strain PCC 6803. *Appl Environ Microbiol.*, 79(8), 2833-2835.
53. Gottesman S. 1996. Proteases and their targets in *Escherichia coli*. *Annu. Rev. Genet.*, 30, 465-506.
54. Ollinger J, O'Malley T, Kesicki EA, Odingo J, Parish T. 2012. Validation of the essential ClpP protease in *Mycobacterium tuberculosis* as a novel drug target. *J. Bacteriol.*, 194, 663–668.
55. Bukau B, Horwich AL. The hsp70 and hsp60 chaperone machines. *Cell*. 1998;92:351–366.
56. Singh SK, Grimaud R, Hoskins JR, Wickner S, Maurizi MR. 2000. Unfolding and internalization of proteins by the ATP-dependent proteases ClpXP and ClpAP. *Proc Natl Acad Sci U S A*. 97:8898–8903.
57. Thibault G, Tsitrin Y, Davidson T, Gribun A, Houry WA. 2006. Large nucleotide-dependent movement of the N-terminal domain of the ClpX chaperone. *EMBO J.*, 25:3367–3376.
58. Martin A, Baker TA, Sauer RT. 2008. Pore loops of the AAA+ ClpX machine grip substrates to drive translocation and unfolding. *Nat Struct Mol Biol.*, 15(11), 1147-1151.
59. Siddiqui SM, Sauer RT, Baker TA. 2004. Role of the processing pore of the ClpX AAA+ ATPase in the recognition and engagement of specific protein substrates. *Genes Dev.*, 18(4), 369-374.
60. Wu S, Howard ST, Lakey DL, Kipnis A, Samten B, Safi H, Gruppo V, Wizel B, Shams H, Basaraba RJ, Orme IM, Barnes PF. 2004. The principal sigma factor sigA mediates enhanced growth of *Mycobacterium tuberculosis in vivo*. *Mol. Microbiol.* 51, 1551–1562.
61. Hu YM, Coates ARM. 1999. Transcription of two sigma 70 homologue genes, *sigA* and *sigB*, in stationary-phase *Mycobacterium tuberculosis*. *J Bacteriol.* 181:8.

62. Staroń A, Sofia HJ, Dietrich S, Ulrich LE, Liesegang H, Mascher T. 2009. The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family. *Mol Microbiol.*, 74(3), 557-581.
63. Ortega J., Singh,S.K., Maurizi,M.R. and Steven,A.C. (2000) Visualization of substrate binding and translocation by the ATP-dependent protease. *Mol. Cell*, 6, 1515–1521.
- 64 Sugimoto S, Yamanaka K, Nishikori S, Miyagi A, Ando T, Ogura T (2010) AAA+ chaperone ClpX regulates dynamics of prokaryotic cytoskeletal protein FtsZ. *J Biol Chem* 285: 6648–6657.
65. Šali A, and Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.*, 234, 779-815.
66. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. *J Comput Chem.*, 2(13), 1605-1612.
67. Eyal E, Lum G, Bahar I. 2015. The anisotropic Network Model web server at 2015 (ANM 2.0), *Bioinformatics*, 31, 1487-9.
68. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T)method. *Nat Protoc.*, 3, 1101-1108.
70. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J. Mol. Biol.*, 305, 567–580.
71. Bailey TL, Bodén M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW, Noble WS. 2009. "MEME SUITE: tools for motif discovery and searching". *Nucleic Acids Res.*, 37, W202-W208.
72. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. *Nucl. Acids Res.*, **42**(W1), W320-W324.

## Tables

**Table 1: Kinetic parameters of ClpX interactions with anti- $\sigma$  factors**

$\sigma$ /anti- $\sigma$ complex	Association rate constant $(k_a)$ ( $M^{-1}s^{-1}$ )	Dissociation rate constant $(k_d)$ ( $s^{-1}$ )	$K_D$ (M)	$\Delta G$ (kJ/mol)
$\sigma^D$ -RsdA <sub>(1-94)</sub>	$6.4 \cdot 10^4$	$9.2 \cdot 10^{-4}$	$2.8 \cdot 10^{-8}$	-44.66
$\sigma^M$ -RsmA <sub>(1-118)</sub>	$2 \cdot 10^4$	$2.7 \cdot 10^{-3}$	$1.2 \cdot 10^{-7}$	-39.22
$\sigma^K$ -RskA <sub>(1-98)</sub>	$3.3 \cdot 10^4$	$5.5 \cdot 10^{-3}$	$2.2 \cdot 10^{-7}$	-38.69
$\sigma^L$ -RslA <sub>(1-125)</sub>	$3.0 \cdot 10^4$	$4.9 \cdot 10^{-3}$	$2.3 \cdot 10^{-7}$	-38.02

**Table 2: Interactions between  $\sigma^D$ -RsdA degron variants and ClpX**

$\sigma$ /anti- $\sigma$ complex	Association rate constant $(k_a)$ ( $M^{-1}s^{-1}$ )	Dissociation rate constant $(k_d)$ ( $s^{-1}$ )	$K_D$ (M)	$\Delta G$ (kJ/mol)
$\sigma^D$ -RsdA <sub>VAA</sub>	$6.4 \cdot 10^4$	$9.2 \cdot 10^{-4}$	$1.4 \cdot 10^{-8}$	-44.66
$\sigma^D$ -RsdA <sub>GAA</sub>	$4.3 \cdot 10^4$	$5.8 \cdot 10^{-3}$	$1.4 \cdot 10^{-7}$	-35.84
$\sigma^D$ -RsdA <sub>AAA</sub>	$6.8 \cdot 10^3$	$2.7 \cdot 10^{-3}$	$6.9 \cdot 10^{-7}$	-36.49
$\sigma^D$ -RsdA <sub>VDD</sub>	$1.3 \cdot 10^4$	$1.3 \cdot 10^{-2}$	$1.1 \cdot 10^{-6}$	-33.37

**Table 3: ATPase activity of ClpX in the presence of substrates**

<b>anti-<math>\sigma</math> substrates</b>	<b>Specific Activity (<math>\mu\text{M}/\text{min}/\mu\text{g}</math>)</b>
ClpX	$1.9 \pm 0.1$
ClpX+ $\sigma^{\text{D}}$ /RsdA <sub>VAA</sub>	$9.6 \pm 0.1$
ClpX+ $\sigma^{\text{M}}$ /RsmA <sub>GAA</sub>	$5.5 \pm 0.2$
ClpX+ $\sigma^{\text{K}}$ /RskA <sub>AAA</sub>	$3.7 \pm 0.2$
ClpX+ $\sigma^{\text{L}}$ /RslA <sub>AAA</sub>	$3.4 \pm 0.1$
<b>RsdA-degtron variants</b>	
ClpX+ $\sigma^{\text{D}}$ /RsdA <sub>GAA</sub>	$5.9 \pm 0.2$
ClpX+ $\sigma^{\text{D}}$ /RsdA <sub>AAA</sub>	$3.5 \pm 0.1$
ClpX+ $\sigma^{\text{D}}$ /RsdA <sub>VDD</sub>	$2.2 \pm 0.1$
<b>GFP chimeras</b>	
ClpX	$1.4 \pm 0.1$
ClpX+GFP <sub>VAA</sub>	$6.4 \pm 0.1$
ClpX+GFP <sub>GAA</sub>	$2.4 \pm 0.1$
ClpX+GFP <sub>AAA</sub>	$2.0 \pm 0.1$
<b>ssrA peptide</b>	
ClpX	1.5
ClpX+ssrA <sub>VAA</sub>	2.7
ClpX+ssrA <sub>GAA</sub>	1.7



ClpX+ ssrA <sub>AAA</sub>	1.5
---------------------------	-----

**Table 4: ATPase activity of  $\Delta$ NCIpX in the presence of GFP-chimeras**

GFP chimera	Specific Activity ( $\mu$ M/min/ $\mu$ g)
$\Delta$ NCIpX	1.2
$\Delta$ NCIpX+GFP <sub>VAA</sub>	2.3
$\Delta$ NCIpX+GFP <sub>GAA</sub>	1.6
$\Delta$ NCIpX+GFP <sub>AAA</sub>	1.4

**Table 5: Correlation between the expression of *clpX* and anti- $\sigma$  factors\***

Genes	Log phase	Stationary phase	Hypoxia	R.O.S	Vitamin C
<i>rsdA</i>	-0.59 (-1.5)	-0.16 (-0.4)	<b>1 (2.5)</b>	<b>0.96 (2.4)</b>	<b>0.99 (2.5)</b>
<i>rsmA</i>	<b>-0.95 (-2.4)</b>	-0.72 (-1.8)	0.8 (2)	0.32 (0.8)	-0.42 (-1)
<i>rskA</i>	<b>0.99 (2.5)</b>	0.78 (1.9)	<b>0.93 (2.4)</b>	0.38 (0.9)	0 (0.08)
<i>rslA</i>	0.53 (1.3)	<b>0.91 (2.3)</b>	0.54 (1.4)	-0.27 (-0.7)	0.49 (1.3)

Abbreviations: *rsdA*: anti- $\sigma^D$ ; *rsmA*: anti- $\sigma^M$ ; *rskA*: anti- $\sigma^K$ ; *rslA*: anti- $\sigma^L$ .

Legend: Correlation coefficients with values  $>0.9$  are in bold. The numbers in parenthesis indicate t-values. \*These correlations were compiled using microarray data (Geo accession nos. **GSE16146**, **GSE101048** and **GSE8786**).

## Figure legends

**Figure 1: Regulated Intra-membrane proteolysis in *M. tuberculosis*.** (A) Schematic of the Regulated Intra-membrane Proteolysis (RIP) pathway in *M. tuberculosis*. The site-1 protease that has not been identified thus far (step I) triggers the proteolytic cascade by cleaving the Extra-cytoplasmic domain (ECD) of the anti- $\sigma$  factor. After the activity of the site-2 protease, Rip1, the *ssrA*-like motif is exposed and intracellular proteolysis (by the ClpXP2P1 complex, step III) occurs by selectively degrading the anti- $\sigma$  domain (ASD), governing the cellular abundance of Extra Cytoplasmic Function (ECF)  $\sigma$  factors. (B) All ECF anti- $\sigma$ -factors with one trans-membrane helix have a *ssrA*-like degron in the trans-membrane region (TMR). The anti- $\sigma$ -factors used for this analysis were from the published curated dataset (63). The trans-membrane region was identified using the TMHMM server, version 2.0 (70). The degron (inset) is highlighted using the MEME suite (71). (C) Sequence features of the four anti- $\sigma$  domains (cytosolic fragment) of the membrane-associated *M. tuberculosis* anti- $\sigma$  factors (aligned using ESript 3.0) (72). The degron at the C-terminus of the cytosolic domain is made accessible after Rip1 proteolysis (step II); Rip1 activity dissociates the  $\sigma$ /anti- $\sigma$  complex from the membrane.

**Figure 2: SPR sensorgrams of ClpX interactions with the four  $\sigma$ /anti- $\sigma$  complexes.** (A) Schematic representation of the *M. tuberculosis*  $\sigma$  factors in complex with the membrane anchored anti- $\sigma$  factors. (B) SPR sensorgram of  $\sigma^D$ /RsdA-ClpX interactions.  $\sigma^D$ /RsdA binds the tightest to ClpX with an affinity *ca* 14.5nM. (C) A ten-fold reduction in the binding affinity was seen in the binding of  $\sigma^M$ /RsmA with ClpX (corresponding to a  $K_D$  of  $1.33 \times 10^{-7}$  M). (D) The binding of  $\sigma^K$ /RskA with ClpX is intermediate between  $\sigma^M$ /RsmA and  $\sigma^L$ /RslA (*ca* 164nM). (E) Interaction of  $\sigma^L$ /RslA with ClpX reveals substantial

reduction in the binding affinity when compared to  $\sigma^D$ /RsdA. The interaction data is compiled in Table 1. Details of the protein constructs are described in supporting information Table A4.

**Figure 3: Sequence and conformational features that influence ClpX substrate recruitment in the absence of adaptor proteins (A-B)** SPR measurements of  $\sigma^D$ /RsdA<sub>AAA</sub>-ClpX and  $\sigma^D$ /RsdA<sub>GAA</sub>-ClpX interactions reveal that  $\sigma^D$ /RsdA<sub>AAA</sub> and  $\sigma^D$ /RsdA<sub>GAA</sub> bind to ClpX with ten-fold lower affinity when compared to the  $\sigma^D$ /RsdA<sub>VAA</sub> complex. The binding affinity of the  $\sigma^D$ /RsdA<sub>AAA</sub> complex is equal to the  $\sigma^L$ /RslA complex. **(C)** Charged residues at the terminal end of the degron substantially reduce ClpX-substrate interaction. The affinity of the  $\sigma^D$ /RsdA<sub>VDD</sub> complex is hundred-fold lower than that for the  $\sigma^D$ /RsdA<sub>VAA</sub> complex.


**Figure 4: The degron influences the unfoldase activity of *M. tuberculosis* ClpX.** **(A)** The ATPase activity of ClpX is altered by the presence of substrates- with maximum activity for the  $\sigma^D$ /RsdA<sub>VAA</sub> substrate and the lowest for the  $\sigma^D$ /RsdA<sub>VDD</sub> mutant. **(B)** The degron attached to polypeptides of equal length also shows degron-dependent gradation in ATPase activity. ATPase activity of ClpX increases only in the presence of the degron peptide ending with ‘VAA’. No change in ATPase activity was observed for degrons with either ‘GAA’ or ‘AAA’. **(C)** GFP chimeras mimic the anti- $\sigma$  substrates in inducing degron dependent gradation in unfoldase activity. The relative decrease in fluorescence was highest for GFP<sub>VAA</sub> followed by GFP<sub>GAA</sub> and GFP<sub>AAA</sub> for both full-length ClpX and  $\Delta$ NClpX. Details of protein constructs are compiled in supporting information Table A4. **(D)** Removal of the ClpX N-terminal domain reduces degron-dependent change in ClpX activity. \*\* indicates significance at  $p < 0.005$ , \*\*\* indicates significance at  $p < 0.0001$ .

**Figure 5: ClpX governs intracellular levels of membrane associated ECF  $\sigma$  factors.** **(A) ClpX and not ClpC1 governs the degradation of an anti- $\sigma$  factor with a *ssrA*-like degron.** For a comparison of the proteolysis of RsdA from the  $\sigma^D$ /RsdA complex by the ClpXP2P1 and ClpC1P2P1 complexes, samples were analyzed for proteolysis at different time-points. This comparison suggests that RsdA is


selectively proteolyzed by the ClpXP2P1 assembly. Targeted proteolysis was less pronounced with the ClpC1P2P1 assembly. The reaction mixture consisted of ClpX/ ClpC1: 0.3  $\mu$ M, ClpP2P1: 0.8  $\mu$ M, ATP (5 mM),  $\sigma^D$ /RsdA substrate: 5.0  $\mu$ M and an ATP-regeneration system (0.32 mg/ml Creatine kinase and 16 mM Creatine phosphate). Immunoblots were performed using antibodies raised against purified recombinant  $\sigma^D$  and RsdA. The ATPase activity of both unfoldases (ClpX and ClpC1) is similar. **(B) qPCR experiments reveal that the mRNA levels of all ECF  $\sigma$  factors increase upon ClpX induction.** The differences observed in the mRNA levels of *sigM* and *sigK* upon ClpX induction are broadly consistent with the relative degradation rates of their cognate anti- $\sigma$  factors. Results shown here depict data from late stationary phase \* indicates significance at  $p < 0.05$ , \*\* indicates significance at  $p < 0.005$ .

**Figure 6: Mechanistic model for the gradient mechanism in the Regulated Intra-membrane Proteolysis (RIP) pathway. (A) Fold change in mRNA levels of ECF  $\sigma$  factors and representative genes from their regulons.** While the expression of all ECF  $\sigma$  factors was upregulated upon ClpX induction, changes in the expression levels of representative genes (*rpfC*, *esxE*, *mpt70* and *mpt53*) in the target regulons is less pronounced (34,44-46). Multiple factors are likely to contribute to this non-linear response. Activation of  $\sigma^K$  and  $\sigma^L$  is also affected by redox stimuli (25,26). Other factors governing activation of  $\sigma^M$  remain to be determined. \* indicates significance at  $p < 0.05$ . **(B) A mechanistic model for degron-dependent variation in ClpX activity.** The rate of anti- $\sigma$  factor degradation controls the cellular abundance of free ECF  $\sigma$  factors. Differences in the intracellular level of free  $\sigma$  factors alter the expression profile.


# Figure 1




**(C)**




## Figure 2



### Figure 3




# Figure 4





(A)



Specific Activity ( $\mu\text{M}/\text{min}/\mu\text{g}$ )	ClpX	ClpC1
	$1.9 \pm 0.1$	$1.7 \pm 0.05$

(B)

